The FDA has expanded the approved indication for Anktiva (nogapendekin alfa inbakicept-pmln) in combination with BCG, now covering adults with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) that features high-grade papillary-only tumors. This builds on the drug's original 2024 approval, which was limited to BCG-unresponsive NMIBC with carcinoma in situ (CIS), with or without papillary tumors.

What makes this approval notable is the FDA's methodology: rather than requiring new efficacy data from a papillary-only cohort, the agency extrapolated from existing CIS trial data, citing the overlapping clinical features of both tumor types — both are aggressive urothelial carcinomas that frequently coexist and carry high recurrence risk in the BCG-unresponsive setting.

By the Numbers:

• 62% complete response rate in the QUILT-3.032 trial (n = 77)
• 58% of responders maintained response for ≥12 months
• 40% of responders maintained response for ≥24 months
• ≥15% of patients experienced adverse events including elevated creatinine, dysuria, hematuria, and urinary tract infection
• Maximum treatment duration: 37 months

Why it matters: This expanded label gives oncologists a new treatment option for a broader group of bladder cancer patients who have failed BCG therapy — a population with limited alternatives and high risk of disease progression. The FDA's willingness to extrapolate efficacy data across tumor subtypes also signals a potentially more flexible regulatory approach for future oncology approvals.